11β-Hydroxysteroid Dehydrogenase Type 1 Inhibition in Idiopathic Intracranial Hypertension: A Double-Blind Randomized Controlled Trial
(2020)
Journal Article
Tomlinson, J. W., Markey, K., Mitchell, J., Botfield, H., Ottridge, R. S., Lavery, G. G., Mollan, S. P., Sinclair, A. J., Arlt, W., Matthews, T., Krishnan, A., Woolley, R., Westgate, C., Yiangou, A., Scotton, W., Fairclough, R., Singhal, R., Stewart, P. M., Taylor, A. E., Alimajstorovic, Z., …Jenkinson, C. (2020). 11β-Hydroxysteroid Dehydrogenase Type 1 Inhibition in Idiopathic Intracranial Hypertension: A Double-Blind Randomized Controlled Trial. Brain Communications, 2(1), Article fcz050. https://doi.org/10.1093/braincomms/fcz050
Treatment options for idiopathic intracranial hypertension are limited. The enzyme 11β-hydroxysteroid dehydrogenase type 1 has been implicated in regulating cerebrospinal fluid secretion, and its activity is associated with alterations in intracrania... Read More about 11β-Hydroxysteroid Dehydrogenase Type 1 Inhibition in Idiopathic Intracranial Hypertension: A Double-Blind Randomized Controlled Trial.